Trending NewsTrending NewsNASDAQ:JSPR Jasper Therapeutics (JSPR) Stock Price, News & Analysis $3.55 -0.13 (-3.53%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$3.57 +0.02 (+0.68%) As of 07/10/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Jasper Therapeutics Stock (NASDAQ:JSPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$3.41▼$3.8450-Day Range$3.02▼$7.0452-Week Range$2.27▼$26.05Volume845,360 shsAverage Volume397,367 shsMarket Capitalization$53.33 millionP/E RatioN/ADividend YieldN/APrice Target$29.75Consensus RatingModerate Buy Company Overview Jasper Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel therapies that target the complement system for the prevention and treatment of rare diseases, organ transplant rejection and certain inflammatory conditions. Its lead product candidate, nomacopan, is an investigational, small‐protein dual inhibitor of complement component C5 and leukotriene B4, designed to address the underlying drivers of tissue damage in disorders such as paroxysmal nocturnal hemoglobinuria (PNH), bullous pemphigoid and cutaneous acute graft-versus-host disease. In addition to nomacopan, Jasper’s pipeline includes earlier-stage complement inhibitors aimed at improving transplant outcomes in kidney and other solid-organ recipients. Founded in 2015 as a spin-out from the University of Pennsylvania and the University of Washington, Jasper Therapeutics completed its initial public offering on the Nasdaq in 2018. The company has established strategic collaborations and license agreements to support global development and commercialization, leveraging partnerships with leading pharmaceutical firms to expand the reach of its complement‐modulating technology. Headquartered in Plymouth, Minnesota, Jasper conducts multi‐center clinical trials across North America, Europe and Australia. Jasper’s management team brings deep expertise in immunology, rare disease development and regulatory strategy. The company is led by a seasoned executive team and board of directors with decades of experience guiding small and mid‐sized biopharmaceutical enterprises through late‐stage clinical trials and toward potential commercialization. This leadership collective underscores Jasper’s commitment to advancing its pipeline and delivering transformative therapies for patients with high‐unmet medical needs.AI Generated. May Contain Errors. Read More Jasper Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreJSPR MarketRank™: Jasper Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 315th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingJasper Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageJasper Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jasper Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jasper Therapeutics are expected to decrease in the coming year, from ($4.47) to ($4.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Jasper Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.23% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Jasper Therapeutics has recently decreased by 10.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.23% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Jasper Therapeutics has recently decreased by 10.98%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment-0.33 News SentimentJasper Therapeutics has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Jasper Therapeutics this week, compared to 3 articles on an average week.Search Interest16 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows19 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 46% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jasper Therapeutics' insider trading history. Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JSPR Stock News HeadlinesWilliam Blair Analysts Raise Earnings Estimates for JSPR1 hour ago | americanbankingnews.comBMO Capital Markets Reaffirms "Market Perform" Rating for Jasper Therapeutics (NASDAQ:JSPR)July 10 at 3:00 AM | americanbankingnews.comYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything… | Crypto 101 Media (Ad)UBS Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)July 9 at 5:21 PM | theglobeandmail.comJasper Therapeutics, Inc.: Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayJuly 9 at 12:20 PM | finanznachrichten.deJasper Therapeutics Cutting Half of Staff After Study SetbackJuly 9 at 12:20 PM | marketwatch.comJasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayJuly 9 at 8:00 AM | globenewswire.comHC Wainwright Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock PriceJuly 9 at 3:01 AM | americanbankingnews.comSee More Headlines JSPR Stock Analysis - Frequently Asked Questions How have JSPR shares performed this year? Jasper Therapeutics' stock was trading at $21.38 at the beginning of the year. Since then, JSPR stock has decreased by 83.4% and is now trading at $3.55. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) issued its quarterly earnings data on Monday, May, 12th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by $0.24. When did Jasper Therapeutics' stock split? Jasper Therapeutics shares reverse split before market open on Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jasper Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings5/12/2025Today7/10/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JSPR CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Jasper Therapeutics$29.75 High Price Target$65.00 Low Price Target$5.00 Potential Upside/Downside+738.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($5.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$71.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-109.45% Return on Assets-89.82% Debt Debt-to-Equity RatioN/A Current Ratio4.31 Quick Ratio4.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.11 per share Price / Book0.86Miscellaneous Outstanding Shares15,020,000Free Float14,331,000Market Cap$53.32 million OptionableOptionable Beta2.69 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:JSPR) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.